Clinical trials
Fabry Disease trials in Australia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
27 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 1 |
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
| Active, not recruiting | 5 |
| Terminated | 4 |
| Recruiting | 2 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amicus Therapeutics | 10 |
| AVROBIO | 2 |
| Idorsia Pharmaceuticals Ltd. | 2 |
| Protalix | 2 |
| Sangamo Therapeutics | 2 |
| Shire | 2 |
| 4D Molecular Therapeutics | 1 |
| Chiesi Farmaceutici S.p.A. | 1 |
| Genzyme, a Sanofi Company | 1 |
| Melbourne Health | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fabry Disease | 27 |
| Lysosomal Storage Diseases | 5 |
| Angiokeratoma | 1 |
| Cardiovascular Diseases | 1 |
| Central Nervous System Diseases | 1 |
| Cerebral Small Vessel Diseases | 1 |
| Cerebrovascular Disorders | 1 |
| Gaucher Disease | 1 |
| Genetic Diseases, Inborn | 1 |
| Kidney Diseases | 1 |
Trials
Showing 51 to 27 of 27. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.